Prefrontal Oscillations in Social Anxiety Disorder (POSAD)

Summary

Experimental fear in rodents is correlated with slow oscillations in electrical recordings of prefrontal cortex activities. The present study aims to test whether slow prefrontal oscillations is a biomarker of pathological anxiety in human subjects.

Conditions

• Anxiety Disorders
• Anxiety
• Anxiety and Fear

Interventions

BEHAVIORAL

In vivo social exposure

Subjects will be invited to give a 5 minutes oral presentation on the topic of their choice to five examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is prompt to elicit anticipation-type of social anxiety.

BEHAVIORAL

Social exposure in a virtual reality setting

Subjects will give a 5 minutes oral presentation on the subject of their choice to a virtual reality panel composed of 5 examiners displaying no facial emotional reaction, after a 5 minutes period of silent waiting in front of the examiners. This waiting period is expected to elicit anticipation-type of social anxiety.

OTHER

EEG recording

EEG will be recorded with a standard 16-electrodes cap. Recordings will start before the 5 minutes waiting period and continue throughout oral presentation and recovery. The recovery period will be used as a baseline control

DIAGNOSTIC_TEST

Psychometric evaluation

Subjects will be evaluated prior to inclusion using the following assessment tools * Anamnestic Association for Methodology and Documentation in Psychiatry (AMDP) questionnaire * Mini International Neuropsychiatric Interview (MINI 6.0, for psychiatric diagnoses) * Liebowitz Social Anxiety Scale (LSAS) * Montgomery Asberg Depression Rating Scale (MADRS) * Brief Anxiety Scale of Tyrer (BAS) * State-Trait Anxiety Inventory (STAI A-B) * Global Assessment of Functioning (GAF)

DIAGNOSTIC_TEST

Visual Analogue Scale of anxiety

Subjects will be asked to rate their anxiety levels * immediately before (5 minutes of silent waiting), * during * and after the 5-minute oral presentation (recovery)

Sponsors & Collaborators

• Institut National de la Santé Et de la Recherche Médicale, France

  lead OTHER_GOV

Principal Investigators

• Olivier Doumy, MD · Centre Hospitalier Charles Perrens, Bordeaux; INRA NutriNeuro, Bordeaux; Université de Bordeaux, France

• Alexandra Bouvard, MD · Centre Hospitalier Charles Perrens, Bordeaux; Université de Bordeaux, France

• Cyril Herry, PhD · Neurocentre Magendie, Inserm U1215, Bordeaux, France

• Cyril Dejean, PhD · Neurocentre Magendie, Inserm U1215, Bordeaux, France

• Thomas Bienvenu, PhD · Centre Hospitalier Charles Perrens, Bordeaux; Neurocentre Magendie, Inserm U1215, Bordeaux, France

• Jacques Taillard, MS · GENPHASS, CHU de Bordeaux

• Bruno Aouizerate, MD-PhD · Centre Hospitalier Charles Perrens, Bordeaux; INRA NutriNeuro, Bordeaux; Université de Bordeaux, France

Study Design

Allocation

NON_RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Model

SEQUENTIAL

Eligibility

Min Age

20 Years

Max Age

50 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-11-12

Primary Completion

2025-11-08

Completion

2026-05-09

Countries

• France

Study Locations